But as of right now, no, we're not doing that
Mounjaro FDA Safety Label Change Ozempic (semaglutide) subcutaneous weekly injection FDA Approval Year: 2017 Ozempic FDA Safety Label Change Rybelsus (active ingredient: semaglutide) once-daily pills FDA Approval Year: 2019 Rybelsus FDA Safety Label Change Soliqua 100/33 (insulin glargine and lixisenatide) subcutaneous daily injection FDA Approval Year: 2016 Soliqua FDA Safety Label Change Trulicity (dulaglutide) subcutaneous weekly injection FDA Approval Year: 2014 Clinical trials reports of stomach problems (gastrointestinal effects) added
No oral formulation of retatrutide has been publicly announced or registered in clinical trials as of April 2026 (based on available information from Eli Lilly's published pipeline and ClinicalTrials.gov)
Chemical & physical profile Research code: LY3437943 Class: Triple GIP / GLP-1 / glucagon receptor agonist Molecular formula: C 221 H 343 N 47 O 63 Molecular weight: 4,731.46 g/mol CAS number: 2381089-83-2 Appearance: White to off-white lyophilized powder Purity (HPLC): 99% Plasma half-life (preclinical): ~6 days Storage: 20C lyophilized (24 months)
Eventually: lethargy, stupor, coma
1 GLP-1 medications, like semaglutide, liraglutide, and dulaglutide, have been approved in the U.S
